[Lyposomal form of doxorubicin hydrochloride lypodox in the treatment of lymphogranulomatosis and non-Hodgkin's lymphomas].
The article focuses on the possibility of our employing the drug preparation lypodox, a lyposomal form of doxorubicini hydrochloridum, of the Byolek firm, in treating of Hodgkin's disease and non-Hodgkin's lymphomas. A comparative analysis was performed of efficacy and ill effects of lyposomal and free forms of doxorubicini hydrochloridum. It has been shown that by clinical effectiveness the drug preparation lypodox, doxorubicini hydrochloridum in a lyposomal form, is superior to doxorubicini hydrochloridum in a free form in resistant and aggressive forms of Hodgkin's disease and non-Hodgkin's lymphomas. Side reactions developing in the wake of lypodox administration do not threaten the life and health of patients; these do not preclude us from employing the drug in a clinical setting.
O V
OV
Ponamareva
L P
LP
Kindzel'skiĭ
G I
GI
Kulik
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001772:Blood Cell Count; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006689:Hodgkin Disease / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D008081:Liposomes; D008228:Lymphoma, Non-Hodgkin / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
D008081:Liposomes; D004317:Doxorubicin